Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Polynovo Ltd (ASX: PNV) is an Australian-based medical device company that designs, develops and manufactures dermal regeneration solutions.
Its flagship patented NovoSorb biodegradable polymer technology is used to develop innovative medical devices that help surgeons treat patients with traumatic wounds. The company also has a development program covering breast sling, hernia, and orthopaedic applications.
Investors in the Polynovo share price will be happy to know the company is preparing for growth by expanding its manufacturing facility and headquarters in Melbourne, and establishing high quality processes that enable product innovation.
|23 Jul 2021||$2.27||$0.03||1.34%||2,222,550||$2.26||$2.29||$2.21|
|22 Jul 2021||$2.24||$0.12||5.66%||3,874,479||$2.13||$2.25||$2.12|
|21 Jul 2021||$2.12||$-0.04||-1.85%||2,843,383||$2.18||$2.18||$2.09|
|20 Jul 2021||$2.16||$0.03||1.41%||4,657,163||$2.13||$2.19||$2.13|
|19 Jul 2021||$2.13||$0.07||3.40%||5,840,560||$2.07||$2.16||$2.06|
|16 Jul 2021||$2.06||$-0.04||-1.90%||6,518,910||$2.11||$2.21||$2.04|
|15 Jul 2021||$2.10||$-0.20||-8.70%||6,778,488||$2.29||$2.29||$2.09|
|14 Jul 2021||$2.30||$-0.11||-4.56%||3,873,438||$2.39||$2.41||$2.30|
|13 Jul 2021||$2.41||$0.03||1.26%||5,904,035||$2.49||$2.57||$2.38|
|12 Jul 2021||$2.38||$0.05||2.15%||2,067,786||$2.33||$2.39||$2.30|
|09 Jul 2021||$2.33||$-0.05||-2.10%||2,346,152||$2.33||$2.35||$2.28|
|08 Jul 2021||$2.38||$-0.04||-1.65%||2,404,734||$2.42||$2.45||$2.36|
|07 Jul 2021||$2.42||$0.02||0.83%||1,986,498||$2.45||$2.47||$2.39|
|06 Jul 2021||$2.40||$-0.23||-8.75%||3,976,346||$2.64||$2.64||$2.39|
|05 Jul 2021||$2.63||$-0.06||-2.23%||1,025,799||$2.69||$2.71||$2.62|
|02 Jul 2021||$2.69||$-0.08||-2.89%||798,717||$2.77||$2.78||$2.69|
|01 Jul 2021||$2.77||$-0.05||-1.77%||1,301,931||$2.81||$2.82||$2.72|
|30 Jun 2021||$2.82||$-0.05||-1.74%||1,288,655||$2.89||$2.92||$2.82|
|29 Jun 2021||$2.87||$0.02||0.70%||693,629||$2.83||$2.87||$2.81|
|28 Jun 2021||$2.85||$-0.03||-1.04%||1,688,296||$2.88||$2.88||$2.82|
|26 Mar 2021||Bruce Rathie||Sell||200||$571,220||
|09 Mar 2021||David Williams||Buy||100||$234,000||
|04 Mar 2021||David Williams||Buy||300||$721,198||
|02 Dec 2020||Leon Hoare||Sell||100||$345,400||
On-market trade. As per announcement on 02/12/2020.
|01 Dec 2020||Paul Brennan||Sell||200||$678,000||
On-market trade. As per announcement on 01/12/2020.
|01 Dec 2020||Bruce Rathie||Sell||355||$1,194,478||
|27 Aug 2020||David Williams||Buy||500||$1,020,994||
|Mr David Williams||Non-Executive DirectorNon-Executive Chairman||Feb 2014||
Mr Williams is an experienced Director and investment banker with a record in business development and strategy, as well as in mergers and acquisitions and capital raising. He has 35 years of experience working with and advising ASX-listed companies in the food, medical device and pharmaceutical sectors.
|Mr Bruce Rathie||Non-Executive Director||Feb 2010||
Mr Rathie practised as a partner in legal firm and acted as Senior Corporate Counsel to Bell Resources Limited in its early years. When Head of the Industrial Franchise Group at Salomon Smith Barney he led Salomon's roles in the Federal Government's privatisation of Qantas, Commonwealth Bank (CBA3) and Telstra (T1). He now has over 19 years' experience as a full time professional Non-executive Director. He is currently Chairman of Capricorn Mutual Limited and a Non-executive Director of Capricorn Society Limited.
|Mr Paul Brennan||Managing Director||Feb 2015||
Mr Brennan has knowledge and understanding of the health system through his clinical background and commercial exposure with various multinational companies. He has co-ordinated the marketing, global strategy development, new product development and regulatory processes for the Asia-Pacific region for organisations in relation to medical products and devices. Mr Brennan has knowledge of the manufacturing and production processes. Previously he was Marketing Director Australia and New Zealand and Sales Director New Zealand for Smith & Nephew Healthcare from 2008 to his commencement with PolyNovo in February 2015.
|Dr Robyn Elliott||Non-Executive Director||Oct 2019||
Dr Elliott is currently Executive Director, Strategic Fractionation Program Delivery at CSL Behring. Dr Elliott previously held Strategic Expansion and Quality Senior Director roles within CSL, was the Managing Director at IDT Australia and commenced her career at DBL Faulding. Dr Elliott has experience in product development, clinical trials, regulatory affairs, audits, quality management, project management and operational strategy. Her worldwide experience is in new facility delivery, production scale up, strategy, regulatory affairs and audit.
|Dr David McQuillan||Non-Executive Director||Aug 2012||
Dr McQuillan has technical, medical, scientific and regulatory knowledge, as well as merger and acquisition expertise. Previously he was a Fogerty Fellow at the NIH (Bethesda, MD), an NH&MRC Fellow at the University of Melbourne, and Associate Professor at Texas A&M University (Houston, TX). Dr McQuillan was with LifeCell Inc/Kinetic Concepts Inc (KCI) for 12 years, holding number of senior roles, including Vice President for Research and Development at LifeCell and Senior Vice President of Advanced Research and Technology at KCI. He was Chief Science Officer for TELA Bio from 2013 to 2015. He is currently a Non-executive Director for Cell Care Therapeutics Inc and Non-executive Director and Co-Founder of ECM Technologies Inc.
|Mr Andrew Stuart Lumsden||Non-Executive Director||Jun 2021||
Mr Lumsden is a finance executive with more than 20 years' experience locally and internationally. Andrew is currently Global Chief Operating Officer of Wellcom Group Pty Ltd (formerly Wellcom Group Limited) and since joining Wellcom in 2008 he held roles as Group Financial Controller, Chief Financial Officer and Company Sectretary. Previously he was a Senior Audit Manager for PricewaterhouseCoopers (PwC) in the UK and Australia. Andrew has experience in assurance, governance, mergers and acquisitons, taxation, investor relations and strategic planning.
|Mr Leon Hoare||Non-Executive Director||Jan 2016||
Mr Hoare is the Managing Director of Lohmann & Rauscher, Australia & New Zealand (ANZ), a private EU based medical device company. Previously he was Managing Director of Smith & Nephew ANZ (all divisions) until the end of 2015. He served as President of Smith & Nephew's Asia-Pacific Advanced Wound Management (AWM) businesses for 5 years and was a member of the Global Executive Management for the AWM Division. In his 24 years with Smith & Nephew, he also held roles in marketing, divisional and general management. His career also included a senior role at Bristol-Myers Squibb (in surgical products), and as Vice Chair of Medical Technology Association of Australia.
|Ms Christine Emmanuel||Non-Executive Director||May 2020||
Ms Emmanuel is business development professional with more than 30 years' local and international experience. She is on Springboard Enterprises Life Sciences Council, is a non-executive director on the board of Medical Developments. Ms Emmanuel was most recently Executive Manager of Business Development and Commercial at the CSIRO, having founded and led the management of CSIRO's IP portfolio for over 10 years and managed the growth of the CSIRO equity portfolio for the last 5 years. Previously she was in-house IP Counsel for Unilever in the UK and practised as a patent and trademark attorney for Wilson Gunn (UK) and Davies Collison Cave and Griffith Hack in Melbourne.
|Mr Jan-Marcel Gielen||Chief Financial OfficerCompany Secretary||Dec 2018||
|Jan-Marcel Gielen||Chief Financial OfficerCompany Secretary||
|Hsbc Custody Nominees (Australia) Limited||66,551,382||10.07%|
|J P Morgan Nominees Australia Pty Limited||50,570,980||7.65%|
|Citicorp Nominees Pty Limited||19,619,513||2.97%|
|Moggs Creek Pty Ltd||17,400,000||2.63%|
|Lateral Innovations Pty Ltd||10,924,103||1.65%|
|National Nominees Limited||9,834,664||1.49%|
|Merrill Lynch (Australia) Nominees Pty Limited||9,308,685||1.41%|
|Mr Anthony Shane Kittel & Mrs Michele Therese Kittel||7,922,500||1.20%|
|BNP Paribas Nominees Pty Ltd||6,625,645||1.00%|
|BNP Paribas Nominees Pty Ltd (I)||6,186,654||0.94%|
|Sandhurst Trustees Ltd||5,688,623||0.86%|
|BNP Paribas Noms Pty Ltd||5,375,513||0.81%|
|Mr Paul Gerard Brennan||4,185,095||0.63%|
|Ms Simone Maree Beks||4,185,095||0.63%|
|Commonwealth Scientific And Industrial Research Organisation||4,081,250||0.62%|
|Netwealth Investments Limited||3,809,451||0.58%|
|Mr Paul James Lappin & Ms Siobhan Catherine Lyons||3,254,631||0.49%|
|Mr Laurent Fossaert||3,214,172||0.49%|
|Mr David Kenley||3,139,855||0.47%|
|Dr Marcus James Dermot Wagstaff & Mrs Lara Kate Wagstaff||3,056,377||0.46%|